Study Type definition

Study Type means the nature of the investigation or investigational use for which clinical trial information is being submitted, e.g., interventional, observational.
Sample 1Sample 2Sample 3
Study Type. Rio Puerco Expansion (TP-2008-01) Requestor: PNM Location: Xxxxxxxx County On March 20, 2008, PNM filed with the NMPRC a request under NMPRC Rule 440 to development of a new 345 kV and 115 kV switching station by expanding PNM’s existing Rio Puerco series capacitor station. This project will also consist of the installation of a 345-115 kV bulk transformer, the construction of 13 miles of 115 kV line, and ground clearance improvements to the existing Veranda to Corrales Bluff 115 kV line to allow for a higher thermal ampacity rating. The purpose of this project is to improve system reliability and provide the needed additional transmission delivery source into the fast growing area of southwest Xxxxxxxx County (Northwest Albuquerque and the City of Rio Rancho area) by 2010 to comply with NERC, WECC and PNM Planning and Performance Criteria. The project in-service date is Fall 2010.
Sample 1
Study Type. Installation of a 25 Mar Shunt Capacitor Bank (TP-2008-05) Requestor: PNM Location: Yah-Ta- Hey Switching Station On July 3, 2008, PNM filed with the NMPRC a request under NMPRC Rule 440 to install a 25 Mvar shunt capacitor bank at the Yah-Ta-Hey 115kV switching station to address near-term transmission system voltage problems to comply with NERC, WECC and PNM Planning and Performance Criteria. This upgrade will add voltage support to PNM’s electric transmission system servicing western New Mexico and will maintain adequate and reliable service to existing loads located on that portion of the system. The target completion date for the line upgrade is 2010.
Sample 1

Examples of Study Type in a sentence

  • Low Income Hours of Use and Heating Study Type of Study: Impact EvaluationEvaluation Conducted by: The Cadmus Group, Inc.Date Evaluation Completed: 6/28/2013 Evaluation Objective and High Level Findings: The objective of the study is to assess lighting hours of use (HOU) and the prevalence of secondary heating among low income customers.

  • In addition, by combining this information with other submitted clinical trial registration information (e.g., the Study Type data element), the Agency could confirm whether the pediatric postmarket surveillance of a device product is a clinical trial and indicate which other data elements must be submitted at the time of registration.

  • Study Type 2 and Type 3 package agency compensation model changes to improve opportunities for entrepreneurship in rural Utah and streamline and modernize operations.Licensee Retail Discount.

  • Location Narrative; Roadway Alternatives, Traffic analysis, traffic and transportation technical report per ODOT and FHWA guidance; Bridge Alternative Study; Type, Size, and Location Report.

  • Completed Course of Study Type of Year College/University From To Sem.

  • One of those exposed healthy participants to Δ9- Table 1 Studies included in the review Study Type of study Study sample Cannabinoids investigated Cognitive domain investigated Wade et al.

  • INCITS project types are defined below.• Study (Type S) Project: Study projects are to determine the feasibility and need for a development project which has been proposed to INCITS.

  • Study Name: Walla Walla River Irrigation District Water Conservation Study Type of Feasibility Study: X Water ConservationStorage (Above-Ground) Storage (Other)ReuseStorage (Below-Ground)Requested Grant Amount (must be no more than 50% of Total Study Cost): $ 75,000 Total Cost of Feasibility Study: $ 170,000 Note: Request(s) may not exceed $500,000 per project.

  • Acute Toxicity Profile of Ammonium Thiosulfate Guideline Number Study Type MRID(s) Results Toxicity Category polypnea and dyspnea, languid behavior, hunched appearance, prostration and tremors, rhinorrhea, chromodacryorrhea, and salivation.

  • Therefore, the Study Type for all expanded access use is ‘‘expanded access’’ (see the discussion of§ 11.28(c)).


More Definitions of Study Type

Study Type. Expansion/Upgrade of the Xxxxxxx 115 kV Station (TP-2008-07) Requestor: PNM Location: Xxxxxxx 115 kV Station On August 15, 2008, PNM filed with the NMPRC a request under NMPRC Rule 440 complete certain transmission system enhancements/upgrades in association with the interconnection of the High Lonesome Mesa, LLC (“HLM”) 100 MW nameplate capacity wind-powered electric generation facility (wind generator). The wind generator will be located approximately 13 miles south of the Tri-State Generation and Transmission Association, Inc. (“Tri-State”) Xxxxxxx 115 kV Switching Station (“Willard Station”), near Willard, New Mexico, and will interconnect to the PNM transmission system via Xxxxxxx Station. PNM will complete (or cause to be completed) the following transmission system enhancement/upgrades: • Expansion/upgrade of the Tri-State owned Willard Station, near Willard, New Mexico. • Upgrade of the PNM owned Xxxxxxx to Algodones (“AW”) 115 kV Line. • Rebuild of the PNM owned Xxxxxxx to Belen (“WL”) 115 kV Line. • Installation of a flow control device at the PNM owned Belen 115 kV Switching Station on the Tri-State owned Xxxxx-Xxxxxxx 115 kV Line. HLM has a firm point-to-point transmission service of 100 MW from the wind generator interconnection to the Four Corners 345 kV Switchyard. However, HLM will not be able to fully utilize the 100 MW of transmission service until the PNM transmission system improvements (i.e., the AW 115 kV Line upgrade, rebuild of the WL 115 kV Line, and installation of a flow control device at Belen 115 kV Switching Station on the Belen – Xxxxxxx 115 kV Line) are completed. Until that occurs, conditional firm transmission service will be provided, and the wind generator output will be controlled in response to system reliability directives (either electronic or verbal) issued by PNM. The HLM has been on-line since May 2009. Updates for the remaining transmission system improvements items are listed below: -Rebuild of the PNM owned Xxxxxxx to Xxxxx (“WL”) 115 kV Line by May 2010 - completed -Installation of a flow control device at the PNM owned Belen 115 kV Switching Station on the Tri-State owned Xxxxx-Xxxxxxx 115 kV Line by March 2011 - completed On August 11, 2008 an Large Generator Interconnection Agreement (pursuant to the PNM OATT) was executed between PNM and HLM. Status of PNM’s Transmission Studies 5/28/2010 Study Type: Xxxxxxx Substation (TP-2008-09) Requestor: PNM Location: Cibola County, NM On April 21, 2010, PNM filed wit...
Sample 1
Study Type. Red Mesa Switching Station (TP-2010-01) Requestor: PNM Location: Cibola County, NM On May 14, 2010, PNM filed with the NMPRC a request under NMPRC Rule 440 to complete certain transmission system enhancement/upgrades association with the interconnection of the NextEra Energy Resources LLC (“NextEra”) 102 MW wind generation facility (“Red Mesa Switching Station”). The Switching Station will be located approximately 7 miles west of PNM’s Xxxxxxx Tap on the 115 kV KM transmission line. The purpose of this project is to provide interconnection of a 102 MW wind generation facility to PNM’s 115 xX Xxxx Mesa-Ambrosia transmission line by NextEra by October 2010.
Sample 1
Study Type. A Single Dose Pharmacokinetic Study of Recombinant Human Growth Factor (FGF-1) in Rats Study Director: Xx. Xxxxxx Xxxxxx Sponsor’s Study No: MPI Research Study No.: 0000-000 XXX Research Proposal No.: 04-082217 Study Schedule: Estimated Start Date: November 17, 2004 Estimated Date of Terminal Necropsy: To Be Determined Estimated Audited Draft Report Date: To Be Determined Study Price: $13,900 Original Payment Schedule: Animal Acquisition $8,300 30 Days After Initial Billing $4,200 At Mailing of Audited Draft Report $1,400 THE WORK DESCRIBED IN THIS PROTOCOL WILL BE DONE UNDER THE TERMS AND CONDITIONS OF THE MASTER AGREEMENT BETWEEN MPI RESEARCH AND (Enter Sponsor Here) DATED (Enter Date Here) AND THIS ADDENDUM NO. IS INCORPORATED INTO AND MADE A PART OF SAID MASTER AGREEMENT. MODIFICATIONS TO THE STUDY PRICE, MUTUALLY AGREED UPON IN WRITING BY THE PARTIES, THAT OCCUR DURING THE COURSE OF THE ABOVE DEFINED PAYMENT SCHEDULE WILL BE REFLECTED ON THE NEXT SCHEDULED INVOICE, UNLESS OTHERWISE NOTED. /s/ XXXX XXXXXX /s/ XXXXXXX XXXXXX On behalf of (Enter Sponsor Here) On behalf of MPI Research, Inc.
Sample 1

Related to Study Type

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Protocol means, in respect of any category of object and associated rights to which this Convention applies, the Protocol in respect of that category of object and associated rights;

  • Phase 3 means the period commencing on the day after the Phase 2 implementation date and ending on the Phase 3 implementation date (as defined below).

  • Phase 1 Trial means, with respect to a Licensed Product, a clinical trial (or — in case of a multi-phase clinical trial — those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).

  • Phase III Trial means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.

  • Phase 1 means the first implementation phase of this section, beginning June 1, 2018 and ending May 31, 2022.

  • Tests after Completion means the tests (if any) which are specified in the Contract and which are carried out in accordance with the Specification after the Works or a Section (as the case may be) are taken over by the Procuring Entity.

  • Genetic testing means an analysis of genetic markers to exclude or identify a man as the father or a woman as the mother of a child. The term includes an analysis of one or a combination of the following:

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Timeline means the list of critical dates and actions included in the Introductory Materials.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase III means human clinical trials, the principal purpose of which is to establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory approval.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Clinical review criteria means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a health carrier to determine the necessity and appropriateness of health care services.

  • Acceptance Testing mean the tests, reviews and other activities that are performed by or on behalf of Agency to determine whether the Deliverables meet the Acceptance Criteria or otherwise satisfy the Agency, as determined by the Agency in its sole discretion.

  • Diagnosis of autism spectrum disorder means medically necessary assessments, evaluations, or tests

  • Phase 2 means the second implementation phase of this section, beginning June 1, 2022 and continuing thereafter.

  • Phase III Clinical Trial means a human clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Licensed Product for one or more indications in order to obtain Marketing Approval of such Licensed Product for such indication(s), as further defined in 21 C.F.R. §312.21 or a similar clinical study in a country other than the United States.

  • Phase III Clinical Study means a human clinical study of a product on a sufficient number of subjects that is designed to establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c). 1.185. [***] 1.186. [***]